Aveanna Healthcare (AVAH) Q2 2026 earnings review
Guidance Raised on Volume Growth, But Margin Reality Sets In
Aveanna delivered a solid Q2 with revenue up 13.7%, driven by strong volume across all segments. Management significantly raised FY26 guidance, projecting over $2.68B in sales and $365M in Adjusted EBITDA. However, underneath the headline beat, operating leverage is decelerating. Adjusted EBITDA growth slowed to 8.0% YoY, and consolidated gross margin compressed by 320 basis points. The core issue: caregiver wage inflation and integration costs are outpacing rate enhancements. While the Preferred Payor strategy is successfully driving volume, the cost of funding that growth is becoming evident.
🐂 Bull Case
Volume is expanding rapidly. PDS hours grew 12.3% and HHH total episodes grew 18.5% in Q2. Aligning clinical capacity with higher-reimbursing partners continues to fund caregiver hiring and capture unmet market demand.
Management increased the FY26 Revenue midpoint by ~$40M to >$2.68B, and Adjusted EBITDA by ~$25M to >$365M, signaling high confidence in second-half visibility and the accretive nature of the Family First acquisition.
🐻 Bear Case
Consolidated gross margin fell 320 basis points to 32.6%. The company is being forced to pass through a larger share of its rate enhancements to caregivers to maintain capacity, limiting bottom-line upside.
Despite a 13.7% increase in revenue, Adjusted EBITDA only grew 8.0% in Q2. This is a sharp deceleration from the 25.2% EBITDA growth seen in Q1 and the 54% growth in Q4.
⚖️ Verdict: ⚪
Neutral. The top-line execution and massive guidance raise are undeniable positives. However, the compression in gross margins and the deceleration in EBITDA growth contradict the narrative of infinite operating leverage. Investors must monitor whether the wage inflation pressures represent a permanent structural shift.
Key Themes
Preferred Payor Strategy Driving Volume
Stable. Aveanna's strategy of shifting volumes to higher-reimbursing Managed Care Organizations (MCOs) continues to pay off. By leveraging enhanced rates to pay higher wages, the company is unlocking critical clinical capacity. This drove a 12.3% YoY increase in PDS hours (to 12.4M) and an 18.5% YoY increase in HHH episodes (to 14.7k).
PDS Margin Compression Exposes Wage Pressures
Decelerating. A major red flag emerged in the core PDS segment: gross margin fell from 32.5% to 28.9%. Cost of revenue per hour grew 7.8% YoY ($31.74), significantly outpacing the 1.7% growth in revenue per hour ($44.62). Even adjusting for a one-time $6M legal settlement reversal that artificially inflated Q2 2025 numbers, the spread rate contracted. The company is trading margin percentage for absolute volume growth.
Inorganic Growth Injection
Accelerating. The guidance raise to >$365M in Adjusted EBITDA strongly implies that the Family First acquisition (estimated ~$120M annual revenue) closed successfully and is immediately accretive. Management has proven they can efficiently integrate tuck-ins (like Thrive Skilled Pediatrics) to densify their footprint in key states like Florida.
AI & Automation in Revenue Cycle
Stable. The company continues to benefit from its ongoing rollout of AI and automation tools to process referrals (handling thousands of e-faxes weekly) and manage its revenue cycle. This structural improvement is keeping corporate expenses relatively flat (down 1.3% YoY in Q2) despite double-digit revenue growth, offering a crucial offset to the field-level margin compression.
Macro: State Medicaid Budget Headwinds
Stable. Management has previously warned that the era of massive, double-digit state Medicaid rate enhancements is over. Moving forward, the company must rely heavily on commercial MCO negotiations, as state budgets tighten and rate wins revert to modest, low single-digit 'cost-of-living' adjustments.
High Debt Burden in a Slower Cash Flow Quarter
Stable. While deleveraging is a priority, Aveanna still carries $1.48 billion in debt. Total interest expense for the first six months was $56.9M, consuming a massive portion of the $149.3M operating income. Free cash flow of $75.4M for the first half is healthy, but leaves little margin for error if aggressive acquisitions strain liquidity.
Other KPIs
Stable. Generated from $85.3M in operating cash flow, less ~$10M in CapEx and principal payments. This provides necessary liquidity for the Family First acquisition while servicing the heavy debt load.
Decelerating slightly. Dropped 110 basis points YoY from 55.0%. Despite a healthy shift toward higher-paying episodic mix (81.0% vs 74.5% a year ago), revenue per completed episode actually fell slightly (-0.9%), indicating Medicare rate pressures are capping upside.
Accelerating. The MS segment continues its turnaround, with spread rate up 4.0% YoY. The Preferred Payor playbook is working here, pushing segment gross margin to 45.1% and proving the model translates beyond core nursing.
Guidance
Accelerating. Upgraded from previous guidance of $2.63B-$2.65B. Represents at least 10.1% YoY growth vs FY25's $2.43B. The raise largely reflects the inclusion of the Family First acquisition alongside steady organic execution.
Accelerating. Upgraded massively from previous guidance of $338M-$342M. Represents at least 13.8% YoY growth vs FY25's $320.8M. Achieving this will require swift synergy realization from recent M&A to offset the underlying gross margin compression seen in Q2.
Key Questions
Margin vs Volume Trade-off
PDS gross margin fell 360 basis points YoY. How much of this compression is permanent due to required wage pass-throughs, and what is the new normalized margin target for the segment?
Organic vs Inorganic Guidance Contribution
You raised FY26 Adjusted EBITDA guidance by roughly $25 million. How much of this increase is directly attributable to the Family First acquisition closing, versus an organic beat in the base business?
Medicare Home Health Moratorium Impact
While previously stated to have 'zero impact' on current plans, has the nationwide CMS moratorium on new Medicare home health and hospice providers shifted M&A target valuations or altered the competitive landscape in HHH?